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Monitoring of oral and nasal exhaled nitric oxide in
eosinophilic chronic rhinosinusitis: A prospective study
Noriaki Noda, M.D., Sachio Takeno, M.D., Ph.D, Takashi Fukuiri, M.D., and
Katsuhiro Hirakawa, M.D., Ph.D
ABSTRACT
Background: We aimed to examine the effect of different therapeutic modalities on levels of fractional concentrations of exhaled nitric oxide (FeNO) in
patients with eosinophilic chronic rhinosinusitis (ECRS).
Methods: Thirty-six ECRS patients with nasal polyps were treated either medically or surgically. Oral and nasal FeNO levels were measured using an
electrochemical NO analyzer initially and at 1 and 6 months. The mRNA expression and localization of nitric oxide synthase (NOS) isoforms in sinus mucosa
and nasal polyps were analyzed by real-time polymerase chain reaction (PCR) and immunohistochemistry.
Results: The mean oral FeNO levels in the surgical group had decreased significantly from 50.9 to 36.8 ppb 6 months after endoscopic sinus surgery. All
patients in this group showed significantly higher nasal FeNO levels after treatment. The mean nasal FeNO levels were 62.3 ppb at 1 month and 93.6 ppb
at 6 months. Mean oral and nasal FeNO levels in the medical group after treatment remained unchanged when compared with the baseline levels. Positive
immunoreactivity of inducible NOS (iNOS) was observed in both epithelial cells and submucosal inflammatory cells. Real-time PCR analysis showed
significant up-regulation of iNOS and IL-5 mRNA expression.
Conclusion: A combination of oral and nasal FeNO measurements is useful to monitor the extent of inflammation in CRS patients. The increase in nasal
FeNO in the surgical group indicates prompt recovery of NO release from healed sinus mucosa through the opened sinus ostia. Reduction of oral FeNO levels
may reflect a cessation of the underlying lower airway inflammation that is characteristic of ECRS.
(Am J Rhinol Allergy 26, 255–259, 2012; doi: 10.2500/ajra.2012.26.3772)
The human paranasal sinuses are the major source of nitric oxide(NO) production and make a large contribution to the NO
levels detected in the nasal cavity.1 In this sense, the monitoring of
fractional concentrations of exhaled NO (FeNO) has the potential to
be a reliable and noninvasive marker of inflammatory conditions in
human nasal airways.2–5 Nasal NO levels are reported to be decreased
in most patients with chronic rhinosinusitis (CRS), but some contra-
dictions remain in the findings, and the results are often heteroge-
neous.6–10
In the present study, we prospectively examined changes in oral
and nasal FeNO levels in patients with eosinophilic CRS (ECRS) after
different therapeutic modalities. ECRS was summarized as an entity
of intractable chronic sinus inflammation accompanied by the infil-
tration of numerous activated eosinophils in the paranasal sinus
mucosa and nasal polyps.11,12 The phenotype of ECRS is applicable
for CRS with nasal polyps in Europe and the United States.13 There is
so far limited information available for changes in FeNO levels after
medical or surgical treatment in ECRS patients. We also carried out a
molecular analysis of paranasal sinus mucosa. The mRNA expression
of three NO synthase (NOS) isoforms and interleukin-5 (IL-5) was
quantitatively analyzed by real-time reverse transcription-polymer-
ase chain reaction (RT-PCR), and the immunohistological localization
of inducible NOS (iNOS) and endothelial NOS (eNOS) was examined.
We found that a combination of the oral and nasal FeNO measure-
ment described here was useful to monitor the clinical course of CRS
patients.
METHODS
Patients
Thirty-six ECRS patients were recruited into a prospective study of
medical (n  12) versus surgical (n  24) therapy. Thirty-two age-
matched normal volunteers served as controls. The diagnosis of ECRS
was based on the clinical symptoms, endoscopic examination, and CT
scanning, in accordance with criteria proposed by the Japanese Rhi-
nological Society.11,12 All patients had shown multiple nasal polyps
and characteristic mucus secretion with high viscosity. None of the
patients had received topical or systemic steroids for at least 4 weeks
before initial visits. Patients who had undergone previous sinus sur-
gery were excluded. The CT images were subjected to radiological
grading using the Lund-Mackay system.14 The total sinus scores were
calculated bilaterally (range from 0 to 24). In the medical group, all
patients received a 6-month course of oral antileukotrienes and intra-
nasal corticosteroid preparations. Endoscopic sinus surgery (ESS) was
performed on patients in the surgical group under general anesthesia.
After the surgery, all patients were prescribed antibiotics for 5–7 days.
After discharge, they received the same treatment as the medical
group on an outpatient basis. Evaluation of postoperative endoscopic
appearance was performed on patients in the surgical group at 6
months.11 They were classified based on the condition of ethmoid
sinus mucosa, i.e., well healed or containing edematous regions. The
study protocol was approved by the Institutional Review Board at the
Hiroshima University School of Medicine.
Measurements of NO
Measurements of the FeNO level were performed using a handheld
electrochemical analyzer (NObreath; Bedfont Scientific, Ltd., Roches-
ter, U.K.) according to the American Thoracic Society/European Re-
spiratory Society guidelines.15,16 For oral FeNO measurements, sub-
jects first inhaled ambient air with a nose clip and then exhaled for 16
seconds at a constant flow rate of 50 mL/s through a disposable
mouthpiece. For nasal FeNO measurements, subjects were advised to
exhale transnasally with their mouth closed into the device with a
nose adaptor as described elsewhere.17 Each measurement was per-
formed in triplicate, and the mean value was used for analysis. The
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patients in both groups were examined at pretreatment and 1 and 6
months after treatment.
Immunohistochemistry
Mucosal specimens from ethmoid sinuses and nasal polyps were
obtained from 12 patients in the surgical group at the time of surgery.
In each case, the specimens were divided and either fixed in 4%
paraformaldehyde for immunohistochemistry or, alternatively, im-
mersed in RNA later solution (Ambion, Austin, TX) for real-time
RT-PCR. Punch biopsies from the inferior turbinate were also per-
formed for PCR analysis. Anti-human iNOS (NOS2) mouse monoclo-
nal antibody (clone 2D2-B2) was from R & D Systems (Minneapolis,
MN), and anti-human eNOS (NOS3) rabbit polyclonal antibody was
from Thermo Scientific (Fremont, CA).
Immunostaining was performed on 5-m-thick cryostat sections.
For antigen retrieval, sections were immersed in Histo VT One (Na-
calai Tesque, Kyoto, Japan) at 70°C for 40 minutes. The sections were
then incubated overnight at 4°C in the presence of the primary
antibodies. The color development was performed using the strepta-
vidin-biotin amplification technique (ChemMate EnVision kit; Dako,
Glostrup, Denmark). Peroxidase activity was visualized by the di-
aminobenzidine solution. Sections were counterstained with Mayer’s
hematoxylin. Negative controls were performed omitting the primary
antibody or using an isotype control antibody from the same species.
Quantitative Real-Time RT-PCR Analysis
Cellular RNA was isolated using RNeasy mini kits (Qiagen, Valen-
cia, CA). For cDNA synthesis, total RNA was reverse transcribed to
cDNA using a High Capacity RNA-to-cDNA kit (Applied Biosystems,
Foster City, CA) according to the instructions supplied by the man-
ufacturer. Gene expression was measured on a 7300 real-time PCR
system (Applied Biosystems) using TaqMan Gene Expression Assays.
PCR primers for neuronal NOS (NOS1; Hs00167223_m1), iNOS
(NOS2; Hs01075529_m1), eNOS (NOS3; Hs01574659_m1), and IL-5
(Hs00174200_m1) were used. PCR primers for GAPDH (Hs99999905_
m1) were used as the reference gene. The results were analyzed using
the comparative cycle threshold (Ct) method (2-Ct). PCR cycles
were run in triplicate for each sample. The Ct values for NOS1, NOS2,
NOS3, and IL-5 were normalized to the value of GAPDH by calcu-
lating the change in Ct (Ct). The mRNA expression levels were then
quantified by calculating 2-Ct to account for the exponential am-
plification of the PCR. For quantification of mRNA levels, the average
values obtained from the inferior turbinate were designated as one
arbitrary unit.
Data Analysis
For multiple comparisons, screening of data for differences was
first performed using ANOVA. If the analysis gave a significant
result, further comparison was performed by the Mann-Whitney U
test for between-group analysis. The comparison between each visit
was assessed with the Wilcoxon rank sum test. A value of p  0.05
was considered significant.
RESULTS
Change in FeNO Levels
The baseline characteristics of the study population are summa-
rized in Table 1. No significant difference between the medical and
the surgical groups was found in the baseline data of age distribution,
proportion of asthma, or total CT scores. The ECRS patients in both
groups showed significantly higher oral FeNO levels at pretreatment
as compared with the normal group. On the other hand, there was no
significant difference in nasal FeNO levels among the three groups.
Oral and nasal FeNO levels were assessed preoperatively and at 1
and 6 months after treatment (Figs. 1 and 2). The mean oral FeNO
levels in the medical group after treatment were 44.3 ppb for 1 month
and 36.3 ppb for 6 months and did not show a statistically significant
difference when compared with the baseline levels. The mean oral
FeNO levels in the surgical group were 46.4 ppb at 1 month and 36.8
ppb at 6 months. Twenty of 24 patients in this group showed a
reduction in the oral FeNO level at 6 months, and the differences at
these postoperative visits were both statistically significant. The mean
nasal FeNO levels in the medical group were 59 ppb at 1 month and
62.8 ppb at 6 months and did not show a significant difference when
compared with the baseline levels. On the other hand, nasal FeNO
levels gradually increased after the ESS procedure in the surgical
group. The mean nasal FeNO levels in this group were 62.3 ppb at 1
month and 93.6 ppb at 6 months, and the differences at these visits
were both statistically significant. All patients in this group showed
higher nasal FeNO levels at the 6-month follow-up when compared
with the baseline levels.
In the surgical group, the endoscopic examination revealed edem-
atous mucosa in most patients 1 month after surgery. The findings
showed gradual improvement at the 6-month checkup. We compared
the findings for the endoscopic appearance and the degree of post-
operative FeNO changes in this group (Fig. 3). The examination of the
ethmoid sinus mucosa at 6 months revealed 15 patients who were
well healed and 9 patients with edematous regions. Well-healed
patients tended to show a pronounced reduction in the oral FeNO
levels and an increase in the nasal FeNO levels. However, the differ-
ence was not significant (p  0.11 for oral FeNO; p  0.18 for nasal
FeNO).
Immunohistological Findings
Figures 4 and 5 show representative immunohistological images of
the distribution of iNOS and eNOS cells in the ethmoid sinus
mucosa and nasal polyps. In general, positive iNOS immunoreactiv-
ity was distinctly observed in ciliated epithelial cells, mainly in their
Table 1 Background and baseline characteristics of the study population
Normal Control ECRS Patients
Medical Group Surgical Group
No. 32 12 24
Age 50 (30–78) 57.9 (44–77) 56.2 (32–75)
Asthma — 9 14
CT score — 14.2 (7–21) 16.9 (10–24)
Oral FeNO (ppb) 14.8 (2–40) 40.1 (8–116)* 50.9 (7–103)*
Nasal FeNO (ppb) 45.4 (15–98) 59.3 (30–123) 50.6 (12–130)
Data are shown as mean with ranges in parenthesis.
*p  0.01 indicates significant difference compared with the control group. Oral and nasal FeNO values in ECRS patients were measured before treatment.
ECRS  eosinophilic chronic rhinosinusitis; FeNO  fractional exhaled nitric oxide.
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cytoplasm. A number of inflammatory cells, more or less widespread
in the submucosal area, with eosinophils being predominant in the
ethmoid sinus mucosa, also revealed positive staining. On the other
hand, eNOS expression was constantly found to be positive in ciliated
epithelial cells and endothelial cells around the capillary vessels. No
significant eNOS staining was observed in submucosal inflammatory
cells.
Real-Time RT-PCR Analysis
Quantitative real-time PCR was conducted to determine three NOS
isoforms and IL-5 mRNA levels (Fig. 6). The ECRS patients showed
significant up-regulation of iNOS and IL-5 mRNA expression in both
ethmoid sinus mucosa and nasal polyps when compared with the
inferior turbinate. On the other hand, mRNA levels for neuronal NOS
(nNOS) and eNOS showed similar profiles to those of the inferior
turbinate. In addition, a statistically significant difference was seen in
the level of iNOS mRNA expression from these patients, with eth-
moid sinus mucosa showing higher levels of mRNA expression com-
pared with nasal polyps.
DISCUSSION
In this study, both upper and lower airway FeNO levels were
measured sequentially in a short period of time using a handheld
analyzer. Several reports indicate that nasal exhaled NO tends to
decrease in patients with acute and chronic sinusitis, mainly because
of hampered ventilation of gaseous NO through occluded sinus os-
tia.6,18,19 Weschta et al.19 recently assessed oral and nasal FeNO levels
in CRS patients using a handheld NO analyzer. They found that, in
CRS patients, mean oral FeNO (23.9 ppb) was higher than in controls
(15.6 ppb), whereas CRS patients with nasal polyps had lower nasal
FeNO levels (19.7 ppb) than did healthy controls (40.3 ppb). The
results of previous studies on FeNO levels are in line with those of the
present study. We also found significantly higher oral FeNO levels at
pretreatment in the ECRS patients when compared with those in
normal subjects. On the other hand, there was no significant differ-
ence in the nasal FeNO levels among the three groups. We consider
that the unchanged nasal FeNO levels in ECRS patients despite im-
paired sinus ostial patency before treatment might be related to
augmented NO production in the inflamed paranasal sinus mucosa.
This idea is supported by the present immunohistological and RT-
PCR findings, which indicated the consistent expression of increased
iNOS activity in the sampled specimens. Elevated levels of oxidized
NO metabolites such as nitrite (NO2
), nitrate (NO3
), and peroxyni-
trite (ONOO) have been detected in CRS patients.20 Such an amount
of NO metabolites could be autotoxic for the surrounding epithelium
and lead to persistency of the disease.
The beneficial outcomes of ESS have been well described in ECRS
patients.21 In addition, to prevent disease recurrence, supplementary
Figure 1. Time-course changes in the level of oral fractional concentration of
exhaled nitric oxide (FeNO) in eosinophilic chronic rhinosinusitis (ECRS)
patients in the (a) medical group and (b) in the surgical group before and at
1 and 6 months after treatment. Time-dependent changes in each patient are
indicated by connecting the individual points. Bars indicate mean values.
*p  0.5; **p  0.01.
Figure 2. Time-course changes in the level of nasal fractional concentration
of exhaled nitric oxide (FeNO) in eosinophilic chronic rhinosinusitis (ECRS)
patients (a) in the medical group and (b) in the surgical group before and at
1 and 6 months after treatment. Time-dependent changes in each patient are
indicated by connecting the individual points. Bars indicate mean values.
*p  0.5; **p  0.01.
Figure 3. Comparison of the endoscopic appearance and the degree of post-
operative fractional concentration of exhaled nitric oxide (FeNO) changes in
the surgical group. Bars indicate mean values.
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medical treatment such as the use of topical steroids and antileukot-
rienes is often necessary. Therefore, the time course measurement of
FeNO levels may provide an objective tool for evaluating the thera-
peutic response of ECRS. Ragab et al.22 found an inverse correlation
between nasal NO levels and the extent of sinus disease in untreated
CRS patients. In their study, after both medical and surgical treat-
ment, the percentage rise in nasal NO levels correlated with changes
in symptom scores, endoscopic changes, and surgical scores. How-
ever, there was no significant correlation with age, sex, smoking
status, or allergy. In the present study, the nasal FeNO levels in the
ECRS patients also increased as a consequence of a combination of
medical and surgical therapies, thus suggesting that treatment may
result in recovery of a high output NO level from constitutive
sources.8 It could be anticipated that the ciliated epithelium of the
paranasal sinuses regained its normal ability to produce NO that
passed through the sinus ostia.
The higher prevalence of bronchial asthma in ECRS patients was
associated with increased oral FeNO levels than those in normal
controls (mean, 46.8 ppb versus 14.8 ppb). This represents a larger
production of endogenous NO derived from lower airways in these
patients. Interestingly, the mean oral FeNO levels in the surgical
group showed a significant reduction of 20% at 6 months. The
results are consistent with a recent study by Delclaux et al.23 showing
improvement in nasal polyposis after treatment not only to increase
nasal but also to decrease bronchial NO concentrations. The interpre-
tation of oral FeNO levels for clinical applications is a topic gaining a
lot of attention. The recent American Thoracic Society guidelines
suggest a reduction of at least 20% or 10 ppb in FeNO to indicate a
significant response to anti-inflammatory therapy from one visit to
the next.24 However, further studies are required to objectively assess
time-course changes in the lower airway function in these patients.
In the present study, ECRS patients showed increased iNOS and
IL-5 mRNA expression. On the other hand, mRNA levels for consti-
tutive NOS isoforms appeared to be unchanged. NO in human para-
nasal sinuses is mainly produced by iNOS activities by the ciliary
epithelium under normal conditions and by inflammatory cells in
inflammation. The epithelial iNOS expression seems to be necessary
for maintaining ciliary beat frequency at a level sufficient for optimal
mucociliary clearing function.1,20,25 Naraghi et al.25 propose that in
rhinosinusitis, iNOS expression in epithelial cells decreases, but NO
production by iNOS in inflammatory cells increases significantly. In
such a process, the local deposition of NO and its metabolites tends to
increase Th2 cells that promote adherence and accumulation of eo-
sinophils through the release of IL-4 and IL-5.26,27 We hypothesize
that pathological events that occur in ECRS may be partly related to
this mechanism. As previously described, a high amount of NO may
dissolve and metabolize in the acidic aqueous environment of the
sinuses.25
Figure 4. Immunohistological photographs of inducible nitric
oxide synthase (iNOS; NOS2) expression in the ethmoid
sinus mucosa and nasal polyps sampled from a patient in the
surgical group. Ciliated epithelial cells and inflammatory cells
are stained positively. (b) Note that iNOS inflammatory
cells are scattered predominantly in the ethmoid sinus mucosa
(scale bar  20 m).
Figure 5. Immunohistological photographs of endothelial ni-
tric oxide synthase (eNOS; NOS3) expression in the ethmoid
sinus mucosa and nasal polyps sampled from a patient in the
surgical group. (a and c) Ciliated epithelial cells and (b)
vascular endothelial cells are stained positively (scale bar 
20 m).
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The results of the present study imply a variety of roles of NO in
the human nose and paranasal sinuses relevant to airway defense
mechanisms, as well as being an inflammatory mediator. The estab-
lishment of standardized nasal NO measurements in CRS patients
will be of great value to assess healing processes in relation to the
underlying inflammatory status.
CONCLUSION
We prospectively examined the effect of different therapeutic mo-
dalities on FeNO levels in ECRS patients. The patients in the surgical
group showed a significant increase in nasal FeNO levels from the
baseline, indicating the prompt recovery of NO release from healed
sinus mucosa. The reduction of oral FeNO levels in this group may
also reflect a cessation of the underlying inflammation in the lower
airway that is characteristic of ECRS.
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Figure 6. Comparison of mRNA expression in ethmoid (a)
sinus mucosa and (b) nasal polyps from eosinophilic chronic
rhinosinusitis (ECRS) patients by real-time reverse tran-
scription–polymerase chain reaction (RT-PCR). The mRNA
levels of nNOS (NOS1), inducible nitric oxide synthase
(iNOS; NOS2), l NOS (eNOS; NOS3), and interleukin
(IL)-5 are normalized to GAPDH and expressed as ratios
relative to controls (inferior turbinate mucosa; bars indicate
mean values; **p  0.01).
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